Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lymphatic Metastasis 1Locally Advanced Rectal Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1Advanced Solid Tumors 1

Interventions

Indocyanine Green 7Radiotherapy 4Magnetic Resonance Spectroscopy 4Lymph Node Excision 4Cisplatin 4Surgical Procedures, Operative 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3gadofosveset trisodium 2Technetium 2TP protocol 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Nivolumab 2Ipilimumab 2Electroporation 2Conversion to Open Surgery 2Control Groups 2tislelizumab 1radium Ra 223 dichloride 1peposertib 1pembrolizumab 1gewf solution 1encorafenib 1cabozantinib 1binimetinib 1avelumab 1alovudine 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphatic Metastasis × peposertib × Clear all
NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡